Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Buy
57
WVE Quote, Financials, Valuation and Earnings
Last price:
$17.85
Seasonality move
:
-15.24%
Day range:
$17.42 - $18.05
52-week range:
$5.28 - $21.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
27.11x
P/B ratio:
23.85x
Volume:
1.6M
Avg. volume:
9.9M
1-year change:
31.82%
Market cap:
$3B
Revenue:
$108.3M
EPS (TTM):
-$0.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd.
|
$10.5M | -$0.30 | -79.56% | -36.52% | $31.60 |
|
BMGL
Basel Medical Group Ltd.
|
-- | -- | -- | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
$130K | -$0.04 | -- | -- | -- |
|
GPCR
Structure Therapeutics, Inc.
|
-- | -$0.43 | -- | -40.58% | $99.43 |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd.
|
$17.77 | $31.60 | $3B | -- | $0.00 | 0% | 27.11x |
|
BMGL
Basel Medical Group Ltd.
|
$0.53 | -- | $10M | 294.67x | $0.00 | 0% | 1.17x |
|
GDTC
CytoMed Therapeutics Ltd.
|
$1.44 | -- | $16.9M | -- | $0.00 | 0% | 97.64x |
|
GPCR
Structure Therapeutics, Inc.
|
$68.34 | $99.43 | $3.9B | -- | $0.00 | 0% | -- |
|
MNDR
Mobile-health Network Solutions
|
$1.11 | -- | $1.4M | -- | $0.00 | 0% | 0.10x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd.
|
12.99% | 1.535 | 1.67% | 2.40x |
|
BMGL
Basel Medical Group Ltd.
|
-- | 0.000 | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
-- | -0.681 | -- | -- |
|
GPCR
Structure Therapeutics, Inc.
|
0.91% | 1.734 | 0.44% | 13.89x |
|
MNDR
Mobile-health Network Solutions
|
-- | -0.831 | -- | 2.20x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd.
|
$5.4M | -$56.4M | -64.6% | -73.8% | -740.71% | -$46.1M |
|
BMGL
Basel Medical Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
GPCR
Structure Therapeutics, Inc.
|
-$978.3K | -$73.9M | -25.36% | -25.55% | -- | -$52.6M |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -1223.46% | -1223.46% | -- | -- |
Wave Life Sciences Ltd. vs. Competitors
-
Which has Higher Returns WVE or BMGL?
Basel Medical Group Ltd. has a net margin of -707.83% compared to Wave Life Sciences Ltd.'s net margin of --. Wave Life Sciences Ltd.'s return on equity of -73.8% beat Basel Medical Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WVEWave Life Sciences Ltd.70.69% -$0.32 $152.2M BMGLBasel Medical Group Ltd.-- -- -- -
What do Analysts Say About WVE or BMGL?
Wave Life Sciences Ltd. has a consensus price target of $31.60, signalling upside risk potential of 77.83%. On the other hand Basel Medical Group Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Wave Life Sciences Ltd. has higher upside potential than Basel Medical Group Ltd., analysts believe Wave Life Sciences Ltd. is more attractive than Basel Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WVEWave Life Sciences Ltd.13 0 0 BMGLBasel Medical Group Ltd.0 0 0 -
Is WVE or BMGL More Risky?
Wave Life Sciences Ltd. has a beta of -1.719, which suggesting that the stock is 271.88% less volatile than S&P 500. In comparison Basel Medical Group Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WVE or BMGL?
Wave Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Basel Medical Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Wave Life Sciences Ltd. pays -- of its earnings as a dividend. Basel Medical Group Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WVE or BMGL?
Wave Life Sciences Ltd. quarterly revenues are $7.6M, which are larger than Basel Medical Group Ltd. quarterly revenues of --. Wave Life Sciences Ltd.'s net income of -$53.9M is higher than Basel Medical Group Ltd.'s net income of --. Notably, Wave Life Sciences Ltd.'s price-to-earnings ratio is -- while Basel Medical Group Ltd.'s PE ratio is 294.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Wave Life Sciences Ltd. is 27.11x versus 1.17x for Basel Medical Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWave Life Sciences Ltd.27.11x -- $7.6M -$53.9M BMGLBasel Medical Group Ltd.1.17x 294.67x -- --
-
Which has Higher Returns WVE or GDTC?
CytoMed Therapeutics Ltd. has a net margin of -707.83% compared to Wave Life Sciences Ltd.'s net margin of --. Wave Life Sciences Ltd.'s return on equity of -73.8% beat CytoMed Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WVEWave Life Sciences Ltd.70.69% -$0.32 $152.2M GDTCCytoMed Therapeutics Ltd.-- -- -- -
What do Analysts Say About WVE or GDTC?
Wave Life Sciences Ltd. has a consensus price target of $31.60, signalling upside risk potential of 77.83%. On the other hand CytoMed Therapeutics Ltd. has an analysts' consensus of -- which suggests that it could grow by 247.22%. Given that CytoMed Therapeutics Ltd. has higher upside potential than Wave Life Sciences Ltd., analysts believe CytoMed Therapeutics Ltd. is more attractive than Wave Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WVEWave Life Sciences Ltd.13 0 0 GDTCCytoMed Therapeutics Ltd.0 0 0 -
Is WVE or GDTC More Risky?
Wave Life Sciences Ltd. has a beta of -1.719, which suggesting that the stock is 271.88% less volatile than S&P 500. In comparison CytoMed Therapeutics Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WVE or GDTC?
Wave Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoMed Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Wave Life Sciences Ltd. pays -- of its earnings as a dividend. CytoMed Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WVE or GDTC?
Wave Life Sciences Ltd. quarterly revenues are $7.6M, which are larger than CytoMed Therapeutics Ltd. quarterly revenues of --. Wave Life Sciences Ltd.'s net income of -$53.9M is higher than CytoMed Therapeutics Ltd.'s net income of --. Notably, Wave Life Sciences Ltd.'s price-to-earnings ratio is -- while CytoMed Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Wave Life Sciences Ltd. is 27.11x versus 97.64x for CytoMed Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWave Life Sciences Ltd.27.11x -- $7.6M -$53.9M GDTCCytoMed Therapeutics Ltd.97.64x -- -- --
-
Which has Higher Returns WVE or GPCR?
Structure Therapeutics, Inc. has a net margin of -707.83% compared to Wave Life Sciences Ltd.'s net margin of --. Wave Life Sciences Ltd.'s return on equity of -73.8% beat Structure Therapeutics, Inc.'s return on equity of -25.55%.
Company Gross Margin Earnings Per Share Invested Capital WVEWave Life Sciences Ltd.70.69% -$0.32 $152.2M GPCRStructure Therapeutics, Inc.-- -$1.13 $777.1M -
What do Analysts Say About WVE or GPCR?
Wave Life Sciences Ltd. has a consensus price target of $31.60, signalling upside risk potential of 77.83%. On the other hand Structure Therapeutics, Inc. has an analysts' consensus of $99.43 which suggests that it could grow by 45.49%. Given that Wave Life Sciences Ltd. has higher upside potential than Structure Therapeutics, Inc., analysts believe Wave Life Sciences Ltd. is more attractive than Structure Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WVEWave Life Sciences Ltd.13 0 0 GPCRStructure Therapeutics, Inc.10 0 0 -
Is WVE or GPCR More Risky?
Wave Life Sciences Ltd. has a beta of -1.719, which suggesting that the stock is 271.88% less volatile than S&P 500. In comparison Structure Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WVE or GPCR?
Wave Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Wave Life Sciences Ltd. pays -- of its earnings as a dividend. Structure Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WVE or GPCR?
Wave Life Sciences Ltd. quarterly revenues are $7.6M, which are larger than Structure Therapeutics, Inc. quarterly revenues of --. Wave Life Sciences Ltd.'s net income of -$53.9M is higher than Structure Therapeutics, Inc.'s net income of -$65.8M. Notably, Wave Life Sciences Ltd.'s price-to-earnings ratio is -- while Structure Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Wave Life Sciences Ltd. is 27.11x versus -- for Structure Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWave Life Sciences Ltd.27.11x -- $7.6M -$53.9M GPCRStructure Therapeutics, Inc.-- -- -- -$65.8M
-
Which has Higher Returns WVE or MNDR?
Mobile-health Network Solutions has a net margin of -707.83% compared to Wave Life Sciences Ltd.'s net margin of --. Wave Life Sciences Ltd.'s return on equity of -73.8% beat Mobile-health Network Solutions's return on equity of -1223.46%.
Company Gross Margin Earnings Per Share Invested Capital WVEWave Life Sciences Ltd.70.69% -$0.32 $152.2M MNDRMobile-health Network Solutions-- -- $4.1M -
What do Analysts Say About WVE or MNDR?
Wave Life Sciences Ltd. has a consensus price target of $31.60, signalling upside risk potential of 77.83%. On the other hand Mobile-health Network Solutions has an analysts' consensus of -- which suggests that it could grow by 28728.83%. Given that Mobile-health Network Solutions has higher upside potential than Wave Life Sciences Ltd., analysts believe Mobile-health Network Solutions is more attractive than Wave Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WVEWave Life Sciences Ltd.13 0 0 MNDRMobile-health Network Solutions0 0 0 -
Is WVE or MNDR More Risky?
Wave Life Sciences Ltd. has a beta of -1.719, which suggesting that the stock is 271.88% less volatile than S&P 500. In comparison Mobile-health Network Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WVE or MNDR?
Wave Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mobile-health Network Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Wave Life Sciences Ltd. pays -- of its earnings as a dividend. Mobile-health Network Solutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WVE or MNDR?
Wave Life Sciences Ltd. quarterly revenues are $7.6M, which are larger than Mobile-health Network Solutions quarterly revenues of --. Wave Life Sciences Ltd.'s net income of -$53.9M is higher than Mobile-health Network Solutions's net income of --. Notably, Wave Life Sciences Ltd.'s price-to-earnings ratio is -- while Mobile-health Network Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Wave Life Sciences Ltd. is 27.11x versus 0.10x for Mobile-health Network Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWave Life Sciences Ltd.27.11x -- $7.6M -$53.9M MNDRMobile-health Network Solutions0.10x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
89
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.81% over the past day.
Sell
20
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Buy
72
GLTO alert for Dec 30
Galecto, Inc. [GLTO] is down 12.13% over the past day.
